OVERVIEW
YNIOS PHARMA set out to build a platform for oral or parenteral administration of inflammation treatment found in acute situations and chronic inflammatory diseases.
YNIOS PHARMA is developing a preclinical program to demonstrate its effectiveness in modulating acute systemic inflammatory responses, protecting vital organs and promoting faster patient recovery.
These acute systemic inflammatory responses can also develop into different situations such as acute ischemic stroke, acute myocardial infarction, severe acute respiratory syndrome (SARS), pancreatitis, major surgery, trauma and burns.
YNIOS PHARMA is a biotech founded in March 2022 by Philippe Van Wesepoel and Jean François Plucker, the same founders of biotech OLYS Pharma which focusses on topical neuro-cutaneous treatments. *
* Diabetic Peripheral Neuropathic Pain – Neuralgia of the trigeminocervical complex (Migraine) – Low back pain – Sciatica pain – Rheumatoid arthritis pain.
THE FOUNDERS


MANAGEMENT
The founders are the Associate Directors of the company. They combine extensive experience in management, international business development, intellectual property, research and innovation, and partnership strategies.